APA

Wang-Lopez Q., Mouret-Reynier M., Savoye A., Abrial C., Kwiatkowski F., Garbar C., DuBray-Longeras P., Eymard J., Lebouedec G., Vanpraagh I., Penault-Llorca F., Chollet P. & Cure H. (20150713). Is it important to adapt neoadjuvant chemotherapy to the visible clinical response? An open randomized phase II study comparing response-guided and standard treatments in HER2-negative operable breast cancer. : The oncologist.

Chicago

Wang-Lopez Qian, Mouret-Reynier Marie-Ange, Savoye Aude-Marie, Abrial Catherine, Kwiatkowski Fabrice, Garbar Christian, DuBray-Longeras Pascale, Eymard Jean-Christophe, Lebouedec Guillaume, Vanpraagh Isabelle, Penault-Llorca Frederique, Chollet Philippe and Cure Hervé. 20150713. Is it important to adapt neoadjuvant chemotherapy to the visible clinical response? An open randomized phase II study comparing response-guided and standard treatments in HER2-negative operable breast cancer. : The oncologist.

Harvard

Wang-Lopez Q., Mouret-Reynier M., Savoye A., Abrial C., Kwiatkowski F., Garbar C., DuBray-Longeras P., Eymard J., Lebouedec G., Vanpraagh I., Penault-Llorca F., Chollet P. and Cure H. (20150713). Is it important to adapt neoadjuvant chemotherapy to the visible clinical response? An open randomized phase II study comparing response-guided and standard treatments in HER2-negative operable breast cancer. : The oncologist.

MLA

Wang-Lopez Qian, Mouret-Reynier Marie-Ange, Savoye Aude-Marie, Abrial Catherine, Kwiatkowski Fabrice, Garbar Christian, DuBray-Longeras Pascale, Eymard Jean-Christophe, Lebouedec Guillaume, Vanpraagh Isabelle, Penault-Llorca Frederique, Chollet Philippe and Cure Hervé. Is it important to adapt neoadjuvant chemotherapy to the visible clinical response? An open randomized phase II study comparing response-guided and standard treatments in HER2-negative operable breast cancer. : The oncologist. 20150713.